In a note to investors previewing third quarter earnings of medical technology companies in his coverage universe, Canaccord Genuity analyst Jason Mills also identified five companies that, in his view, were most likely to be targeted for M&A over next 12 months. The companies were:
AtriCure (ATRC) – leading A-Fib franchise; new products
HeartWare (HTWR) – burgeoning LVAD player
Spectranetics (SPNC) – attractive lead management business; valuation
Thoratec (THOR) – leading LVAD player
Volcano (VOLC) – robust growth; long growth runway
